<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">evrazkar</journal-id><journal-title-group><journal-title xml:lang="ru">Евразийский Кардиологический Журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Eurasian heart journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2225-1685</issn><issn pub-type="epub">2305-0748</issn><publisher><publisher-name>Евразийская ассоциация кардиологов</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.38109/2225-1685-2020-3-100-105</article-id><article-id custom-type="elpub" pub-id-type="custom">evrazkar-6223</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>КОНТРАСТ-ИНДУЦИРОВАННАЯ НЕФРОПАТИЯ У БОЛЬНЫХ СТАБИЛЬНОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И ОДНОЛЕТНИЙ ПРОГНОЗ</article-title><trans-title-group xml:lang="en"><trans-title>CONTRAST-INDUCED NEPHROPATHY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND 1-YEAR PROGNOSIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5820-1759</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миронова</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Mironov</surname><given-names>O. Iu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Миронова Ольга Юрьевна, к.м.н., доцент кафедры факультетской терапии №1 Института клинической медицины им. Н. В. Склифосовского</p><p>119435, г. Москва, ул. Бол. Пироговская, 6 стр. 1</p></bio><bio xml:lang="en"><p>Olga Iu. Mironova, Cand. of Sci. (Med.), docent of the Department of Faculty Therapy No. 1 </p><p>119435, Moscow, st. Bol. Pirogovskaya, 6, bldg. 1</p></bio><email xlink:type="simple">mironova_o_yu@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0060-095X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сивакова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sivakova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сивакова Ольга Анатольевна, к.м.н., заведующая отделением артериальной гипертонии</p></bio><bio xml:lang="en"><p>Olga A. Sivakova, Cand. of Sci. (Med.), Head of the Department of Arterial Hypertension</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2682-4417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фомин Виктор Викторович, член-корр. РАН, профессор, д.м.н., проректор по клинической работе и дополнительному профессиональному образованию, заведующий кафедрой факультетской терапии №1 Института клинической медицины им. Н. В. Склифосовского</p></bio><bio xml:lang="en"><p>Victor V. Fomin, Corresponding Member of the RAS, Professor, Dr. of Sci. (Med.), Vice-Rector for Clinical Work and Additional Professional Education, Head of the Department of Faculty Therapy No. 1 of the Institute of Clinical Medicine</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ Первый МГМУ им. И. М. Сеченова (Сеченовский Университет) МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный Медицинский исследовательский центр Кардиологии» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2020</year></pub-date><volume>0</volume><issue>3</issue><fpage>100</fpage><lpage>105</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Миронова О.Ю., Сивакова О.А., Фомин В.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Миронова О.Ю., Сивакова О.А., Фомин В.В.</copyright-holder><copyright-holder xml:lang="en">Mironov O.I., Sivakova O.A., Fomin V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.heartj.asia/jour/article/view/6223">https://www.heartj.asia/jour/article/view/6223</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Целью проводимого исследования было определить частоту развития контраст-индуцированной нефропатии (КИН) у больных хронической ишемической болезнью сердца (ХИБС) и прогностическую значимость КИН в течение 1 года.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Были обследованы 462 пациента, страдающих стабильной ХИБС и имеющих показания к проведению исследований с внутриартериальным введением йодсодержащего контрастного вещества. Проводимое исследование являлось проспективным открытым когортным и было зарегистрировано в системе ClinicalTrials. gov под идентификационным номером NCT04014153. Первичной конечной точкой принимали развитие КИН. Вторичными конечными точками стали общая смертность, сердечно-сосудистая смертность, развитие инфаркта миокарда, инсульта, желудочно-кишечного кровотечения (ЖКК), острая декомпенсация хронической сердечной недостаточности (ХСН), проведение операции коронарного шунтирования (КШ), повторного чрескожного коронарного вмешательства (ЧКВ).</p></sec><sec><title>Результаты</title><p>Результаты. КИН развилась у 28 больных (6%). У женщин КИН развивалась в 2 раза чаще, чем у мужчин (9,29% и 4,66%). Отмечалась тенденция к несколько более частому развитию заболевания у больных без ожирения (5,88% и 6,22% соответственно). В изученной выборке обращает на себя внимание тенденция к увеличению риска КИН у больных с анемией (8,9% и 5,7% соответственно, р=0,3649, ОШ 1,633,95% ДИ 0,6507-4,239). При этом имелась тенденция к более частому развитию КИН у больных с повышенным уровнем мочевой кислоты (8% и 5,95%, р=0,6575, ОШ 1,375,95% ДИ 0,3055-5,808). У пациентов с СД частота КИН была на 2% выше. Частота КИН была наибольшей в группе больных, у которых развился ИМ (26,7%) и другие крупными неблагоприятными сердечно-сосудистыми событиями (18,1%). Часто выполнялись повторные реваскуляризации (9,5%) и отмечались эпизоды декомпенсации сердечной недостаточности (7%).</p></sec><sec><title>Вывод</title><p>Вывод. Частота развития КИН у пациентов с ХИБС составила 6%. Через 1 год наблюдения установлено, что развитие КИН у больных ХИБС при внутриартериальном введении контрастного вещества приводит к более частому развитию инфаркта миокарда, повторным ЧКВ и острой декомпенсации сердечной недостаточности в течение года.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. The aim of our study was to assess the prevalence of contrast-induced nephropathy (CIN) in patients with chronic coronary artery disease (CAD) and its 1-year prognostic significance.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 462 patients with chronic CAD and indications to the interventions with intraarterial contrast media administration were included in the study. We conducted a prospective open cohort study (ClinicalTrials.gov NCT04014153). The primary endpoint was the development of CIN. The secondary endpoints were total mortality, cardiovascular mortality, myocardial infarction, stroke, gastrointestinal bleeding, acute decompensation of heart failure, coronary artery bypass grafting, repeat percutaneous coronary intervention.</p></sec><sec><title>Results</title><p>Results. 28 patients (6%) developed CIN. The rate of CIN in female patients was twice higher, than in males (9,29% vs. 4,66%). There was a trend towards less cases of CIN in patients without obesity (5,88% vs. 6,22%). CIN developed more frequently in patients with anemia (8,9% и 5,7%, р=0,3649, ОR 1,633,95% CI 0,6507-4,239). There was a trend to higher incidence of CIN in people with hyperuricemia (8% vs. 5,95%, р=0,6575, ОR 1,375,95% CI 0,3055-5,808). The rate of CIN in patients with diabetes mellitus was 2% higher, then without one. People, who suffered from myocardial infarction after 1 year of follow up, had the highest rate of CIN (26,7%), as well as patients with other major cardiovascular complications (18,1%). The rate of repeat percutaneous coronary interventions was 9,5%, the rate of acute decompensation of heart failure was 7%.</p></sec><sec><title>Conclusion</title><p>Conclusion. The prevalence of CIN in patients with chronic CAD was 6%. After 1 year of follow up the rate of CIN was higher in patients who had myocardial infarction, repeat percutaneous coronary interventions and acute decompensation of heart failure.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>контраст-индуцированная нефропатия</kwd><kwd>контрастиндуцированное острое повреждение почек</kwd><kwd>контраст-ассоциированное острое повреждение почек</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>чрескожное коронарное вмешательство</kwd><kwd>контрастное вещество</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>contrast-induced nephropathy</kwd><kwd>contrast-induced acute kidney injury</kwd><kwd>contrast-associated acute kidney injury</kwd><kwd>coronary artery disease</kwd><kwd>percutaneous coronary intervention</kwd><kwd>contrast</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ronco C, Bellasi A, Lullo L Di. Cardiorenal Syndrome : An Overview. Adv Chronic Kidney Dis [Internet]. 2018;25(5):382–90. Available from: https://doi.org/10.1053/j.ackd.2018.08.004</mixed-citation><mixed-citation xml:lang="en">Ronco C, Bellasi A, Lullo L Di. Cardiorenal Syndrome : An Overview. Adv Chronic Kidney Dis [Internet]. 2018;25(5):382–90. Available from: https://doi.org/10.1053/j.ackd.2018.08.004</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lakhal K, Robert-Edan V, Ehrmann S. In the Name of Contrast-Induced Acute Kidney Injury…. Chest [Internet]. 2020;157(4):751–2. Available from: https://doi.org/10.1016/j.chest.2019.12.009</mixed-citation><mixed-citation xml:lang="en">Lakhal K, Robert-Edan V, Ehrmann S. In the Name of Contrast-Induced Acute Kidney Injury…. Chest [Internet]. 2020;157(4):751–2. Available from: https://doi.org/10.1016/j.chest.2019.12.009</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Caspi O, Habib M, Cohen Y, Kerner A, Roguin A, Abergel E, et al. Acute Kidney Injury After Primary Angioplasty: Is Contrast-Induced Nephropathy the Culprit? J Am Heart Assoc. 2017;6(6):1–10.</mixed-citation><mixed-citation xml:lang="en">Caspi O, Habib M, Cohen Y, Kerner A, Roguin A, Abergel E, et al. Acute Kidney Injury After Primary Angioplasty: Is Contrast-Induced Nephropathy the Culprit? J Am Heart Assoc. 2017;6(6):1–10.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int [Internet]. 2005;68(5):2256–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16221227</mixed-citation><mixed-citation xml:lang="en">Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int [Internet]. 2005;68(5):2256–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16221227</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: The wheel has turned 360 degrees. Acta radiol. 2008;49(6):646–57.</mixed-citation><mixed-citation xml:lang="en">Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: The wheel has turned 360 degrees. Acta radiol. 2008;49(6):646–57.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17(10):2871–7.</mixed-citation><mixed-citation xml:lang="en">Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17(10):2871–7.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int [Internet]. 2010;78(8):803–9. Available from: http://dx.doi.org/10.1038/ki.2010.258</mixed-citation><mixed-citation xml:lang="en">James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int [Internet]. 2010;78(8):803–9. Available from: http://dx.doi.org/10.1038/ki.2010.258</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Coca SG, Zabetian A, Ferket BS, Zhou J, Testani JM, Garg AX, et al. Evaluation of short-term changes in serum creatinine level as a meaningful end point in randomized clinical trials. J Am Soc Nephrol. 2016;27(8):2529–42.</mixed-citation><mixed-citation xml:lang="en">Coca SG, Zabetian A, Ferket BS, Zhou J, Testani JM, Garg AX, et al. Evaluation of short-term changes in serum creatinine level as a meaningful end point in randomized clinical trials. J Am Soc Nephrol. 2016;27(8):2529–42.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl [Internet]. 2012;2(1):3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2157171615310406</mixed-citation><mixed-citation xml:lang="en">KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl [Internet]. 2012;2(1):3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2157171615310406</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. 2018 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2018;25(6):1105–87.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. 2018 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2018;25(6):1105–87.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200m.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200m.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna D, Fitzegarld J, Khanna P, Bae S, Singh M. 2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Non-pharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res [Internet]. 2012;64(10):1431–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3683400%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC368044</mixed-citation><mixed-citation xml:lang="en">Khanna D, Fitzegarld J, Khanna P, Bae S, Singh M. 2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Non-pharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res [Internet]. 2012;64(10):1431–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3683400%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC368044</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Алиментарные анемии. Доклад научной группы ВОЗ. 1970.</mixed-citation><mixed-citation xml:lang="en">Алиментарные анемии. Доклад научной группы ВОЗ. 1970.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McCullough PA. Contrast-Induced Acute Kidney Injury. Crit Care Nephrol Third Ed. 2017;282–8.</mixed-citation><mixed-citation xml:lang="en">McCullough PA. Contrast-Induced Acute Kidney Injury. Crit Care Nephrol Third Ed. 2017;282–8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO Working Group. Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl [Internet]. 2012;2(1):124–38. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGOAKIGuideline.pdf</mixed-citation><mixed-citation xml:lang="en">KDIGO Working Group. Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl [Internet]. 2012;2(1):124–38. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGOAKIGuideline.pdf</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
